01.10.2012 - The European Medicines Association has changed its biosimilars guidelines to make it easier to develop biologic follow-on drugs in both the US and Europe.
The London-based agency said it intends to accept batches of reference medicines sourced from outside the European Economic Area (EEA) in the future. This aims to facilitate the global development of biosimilars and avoid the unnecessary repetition of clinical trials.
Under the current European legal framework, companies developing a biosimilar medicine are required to identify a reference medicine that is or has been authorised in the European Economic Area (EEA) and whose batches are sourced from within the EEA. With the new approach, first announced by Commissioner John Dalli in Malta on 15 June 2012, the Agency will begin to accept reference medicine batches sourced from outside the EEA in certain pre-clinical and clinical studies in the comparability exercise.
A draft version of the new guidance is expectedearly next year. Since biosimilars became reality, EMA has become regardedas the most biosimilar-open agency in one of the biggest pharma markets.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.
04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.
The First Multi-Angle Light Scattering Detector for UHPLC!
The µDAWN™ Multi-Angle static Light Scattering (MALS) detector performs absolute characterization of macromolecules eluting from UHPLC, determining molar mass and size independently of retention time and molecular reference standards. more